



## **Abstract Notices**

The Editor of the *2019 ASCO Annual Meeting Proceedings* has authorized correction of the following:

### **569**

**Notice of Retraction:** “Clinical pharmacogenomic testing impacts therapy decisions and supportive medication choices in breast cancer.”

Abstract 569, published in the *2019 ASCO Annual Meeting Proceedings*, was retracted from publication and presentation at the 2019 ASCO Annual Meeting. The research described in the abstract was performed at the Inova Schar Cancer Institute, part of the Inova Health System, which stopped performing its suite of pharmacogenetic tests in response to a U.S. Food and Drug Administration warning letter.

### **2622**

**Notice of Retraction:** “Breast cancer with insertion or deletion exhibits the immunogenic phenotype.”

Abstract 2622 violated ASCO’s Prior Presentation/Publication Policy and was thus removed from the 2019 ASCO Annual Meeting and retracted from publication in the *2019 ASCO Annual Meeting Proceedings*.

### **3573**

**Notice of Retraction:** “Chemoradiotherapy for anal cancer: A population-based study of treatment interruption, treatment completion, and associated outcomes.”

In updated analyses, the authors discovered that the main exposure (radiation therapy) may have been incorrectly coded into the population-level databases from several individual treatment centers. Some of the coded radiation doses and fractionation numbers are considerably beyond what would be clinically plausible. Until this issue has been resolved, the authors believe the results of their study cannot be considered reliable and thus removed their abstract from presentation at the 2019 ASCO Annual Meeting and retracted the abstract from publication in the *2019 ASCO Annual Meeting Proceedings*.

### **4536**

**Notice of Correction:** “Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).”

Following publication of the abstract in the *2019 ASCO Annual Meeting Proceedings*, Daniel M. Geynisman, of the Fox Chase Cancer Center, was added as a contributing author. The abstract author listing should have read as follows:

Benjamin Miron, Eric Ross, Fern Anari, John O'Neill, Jean Hoffman-Censits, Daniel Geynisman, Matthew Zibelman, Alexander Kutikov, Rosalia Viterbo, Richard Greenberg, David Chen, Costas Lallas, Edouard J. Trabulsi, Katherine Alpaugh, Essel Dulaimi, Erica Golemis, Robert Uzzo, Elizabeth Plimack

**6074**

**Notice of Correction:** "Is there a benefit of adding surveillance imaging to frequent history and physical exams in patients treated definitively for head and neck squamous cell carcinoma?"

The middle initial for author Matthew Lee was corrected. His name should have read Matthew C. Lee, not Matthew Z. Lee.

**e17102**

**Notice of Correction:** "A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution."

The middle initial for author Matthew Lee was corrected. His name should have read Matthew C. Lee, not Matthew Z. Lee.

**e18521**

**Notice of Correction:** "In-hospital mortality in acute promyelocytic leukemia patients: A study of national inpatient sample."

In the Results section, the third sentence should have read "59.5% (n = 258) of patients did not receive chemotherapy."

**e21002**

**Notice of Correction:** "Real-world clinical and economic outcomes among newly-diagnosed Merkel cell carcinoma (MCC) patients initiating first-line (1L) checkpoint inhibitors (CPIs) or chemotherapy (CT) in the Veterans Health Administration (VHA)."

The time period "time on 1L therapy" (i.e., the denominator) was erroneously used to calculate economic outcomes. This resulted in an overestimation of the per patient per month (PPPM) economic outcomes (all-cause healthcare resource utilization [HRU] and costs). These estimates have been corrected to account for the fact that all-cause HRU and costs (2018 USD) PPPM should have been evaluated during time to treatment failure (TTF), that is, time from index date to death or subsequent line of therapy start or until end of follow-up, whichever occurred first. The abstract table and conclusions have been updated accordingly to indicate that despite higher costs, the utilization of newly approved CPIs in 1L setting showed delayed treatment failure and reduced all-cause HRU than with CTs.

**e22528**

**Notice of Correction:** "The importance of surgical margins in dedifferentiated liposarcoma survival."

The spelling of Kevin Nguyen's last name was corrected from "Nguygen" to "Nguyen."

**e23087**

**Notice of Correction** "Effect of pre-treatment anxiety and depression on long term survival of prostate cancer patients treated radically with radiation and hormone therapy."

Lauren Jones, of the Nottingham University Hospital NHS Trust, was added as the first author. The abstract author listing should have read as follows:

Lauren Jones, Micheal O'Cathail, Shaymaa Usama Hosni, Jessica Little, Ashley Cox, Eamonn Fergusson, Santhanam Sundar

**e23180**

**Notice of Correction:** "Differences in quality of life and emotional health by diagnosis among women with early-stage gynecological cancers."

After publication of the abstract, the authors discovered that the measures for depression and anxiety were mislabelled in the table. In row 3, the label should have read "Depression (PHQ-9). In row 4, the label should have read "Anxiety (GAD-7)".

*All errors have been corrected in the online versions of the abstracts on JCO.org and ASCO.org. This notice is updated on a rolling basis, as needed.*